Human HGF (NS0-expressed) GMP Protein組換え体(リコンビナント)タンパク質 | Recombinant Human HGF (NS0-expressed) GMP Protein

＊Manufactured in compliance of the applicable sections of World Health Organization TRS, No 822, 1992 Annex 1, Good Manufacturing Practices for biological products; USP Chapter 1043, Ancillary Materials for Cell, Gene, and Tissue-Engineered Products, and USP Chapter 92, Cytokines used in Cell Therapy Manufacturing.

※本製品は研究用です。研究用以外には使用できません。

GMPグレードRecombinant Human HGF (NS0-expressed) を用いたSDS-PAGE像
1μg/lane of GMP-grade Recombinant Human HGF (Catalog # 294-GMP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing R bands at 34-37 and 60-64 kDa and NR bands at 76-83 kDa, respectively.

GMPグレードRecombinant Human HGF (NS0-expressed) の生物活性
Recombinant Human HGF GMP induces IL-11 secretion by Saos‑2 human osteosarcoma cells. The ED₅₀ for this effect is 0.1-0.5 ng/mL.

※バルク包装品も承ります。お気軽にお問合せ下さい。

R&D Systems社組換え体タンパク質製品では通常ウシ血清アルブミン(BSA)をキャリアタンパク質として加えています。キャリアタンパク質を加えることで組換え体タンパク質の安定性が高まり、使用期限が長くなります。また、より濃度の低い溶液での保管も可能となります。CF製品はBSAが含まれない製品となります。一般的に細胞培養や、ELISAのスタンダードにはBSA含有製品を推奨しています。CF製品はBSAが影響してしまうアプリケーションに推奨されます。

R&D Systems' GMP proteins are produced according to relevant sections of the following documents: WHO TRS, No. 822, 1992 Annex 1, Good Manufacturing Practices for Biological Products; USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and USP Chapter 92, Growth Factors and Cytokines Used in Cell Therapy Manufacturing. R&D Systems' quality focus includes: Manufacturing and testing under an ISO 9001:2008 and ISO 13485:2003 certified quality system Documented processes and QA control of documentation and process changes Personnel training programs Raw material testing and vendor qualification/monitoring Fully validated equipment, processes and test methods Equipment calibration schedules using a computerized calibration program Facility maintenance, safety programs and pest controlMaterial review process for variances Monitoring of stability over product shelf-life R&D Systems strives to provide our customers with the analytical characteristics of each product so that customers may determine whether our products are appropriate for their research. The Certificate of Analysis provided contains the following lot specific information: N-terminal amino acid analysis, SDS-PAGE analysis, mass spectrometry results, and endotoxin level (as determined by LAL assay) performed on each bulk QC lot, not on individual bottlings of each QC lot Post-bottling lot-specific bioassay results (compliance with an established range) and results of microbial bioburden testing (using broth culture, Sabourand's dextrose and blood agar plates with results reported at 3 days and at 7 days) Additional testing and documentation requested by the customer can be arranged at an additional cost. Testing may include, but is not limited to, USP sterility testing, positive identity testing, testing for adventitious agents and testing for residual host cell content.Production records and facilities are available for examination by appropriate personnel on-site at R&D Systems in Minneapolis, Minnesota USA.R&D Systems sells its GMP grade recombinant protein products for research use or further manufacturing use in ex vivo cell therapy applications. They are not for in vivo use or for use as therapeutic or other drugs, biologic products or devices. Please read the following End User Terms prior to using this product.